cbdMD Q2 2023 Results: Net Loss Improves, Costs Plummet

Charlotte-based CBD company cbdMD (AMEX:YCBD) reported its second-quarter fiscal 2023 results late Monday, revealing an improved net loss and significant reductions in selling, general and administrative (SG&A) costs.

"This is one of the best operating results we have had since the company acquired the cbdMD brand…We reduced SG&A expenses by an annualized $24 million year over year," said Ronan Kennedy, cbdMD's Interim CEO and CFO in a press release.

The decrease in SG&A costs represents an annualized spending reduction of $24 million yearly. In addition, the company reported a net loss of $1.4 million on sales of $6.2 million for the quarter, compared to a net loss of $5.0 million on sales of $9.6 million in the same period last year.

Financial Highlights from Q2 Fiscal 2023:

Net sales for Q2 2023 were $6.2 million, a 2.5% increase from the previous quarter.
However, net sales for Q2 2023 were down 35% compared to Q2 2022.
Net sales for the first six months of 2023 were $12.3 million, a significant decrease from $18.9 million in the same period last year.
Direct-to-consumer (DTC) net sales for Q2 2023 were $4.9 million, a 26% decline from Q2 2022.
E-commerce net sales remained flat sequentially.
Wholesale sales for Q2 2023 were $1.35 million, a 15% increase from the previous quarter.
However, wholesale net sales were down 56% compared to Q2 2022.
The company reduced SG&A costs by $6.0 million compared to Q2 2022, representing $24 million in annualized spending reductions.
Loss from operations for Q2 2023 improved by approximately $3.6 million or 72% compared to Q2 2022.
Non-GAAP adjusted operating loss for Q2 2023 was approximately $0.8 million, showing an improvement of $1.8 million sequentially.
Loss from operations for the first six months of 2023 was approximately $5.4 million, a decrease from $30.2 million in the same period last year.
Non-GAAP adjusted operating loss for the first six months of 2023 was $3.5 million, down from $8.8 million in the prior year's comparative period.

Price Target

cbdMD stocks were trading 6.65% lower on Monday, after market close, at $2.03 per share.

Benzinga

Benzinga

Financial Highlights from Q2 Fiscal 2023:

Price Target

See Also: